Clinical trial
Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent…
NCT02484443 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT02484443 |
|---|---|
| Title | Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma |
| Official title | A Phase 2 Study of Human-Mouse Chimeric Anti-disialoganglioside Monoclonal Antibody ch14.18 (Dinutuximab, NSC# 764038) in Combination With Sargramostim (GM-CSF) in Patients With Recurrent Osteosarcoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Malignant Neoplasm in the Lung, Metastatic Osteosarcoma, Recurrent Osteosarcoma |
| Intervention type | Biological, Other |
| Interventions | Dinutuximab, Laboratory Biomarker Analysis, Pharmacological Study, Sargramostim |
| Enrollment | 41 |
| Start date | Feb 4, 2016 |
| Primary completion | Mar 31, 2020 |
| Completion | Sep 30, 2023 |
| First posted | Jun 29, 2015 |
| Last update posted | Oct 26, 2023 |
| Countries | Australia, Canada, New Zealand, Puerto Rico, United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: